维普期刊资源整合服务平台（V6.5）

43篇 您的检索式：作者名="Reckamp K"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Non-small cell lung cancer in the elderly: defining treatment options显示文摘	Vora N Reckamp K L	2008	Semin Oncol2008，35，6：	1
2	Akt inhibitors in clinical development for the treatment of cancer显示文摘	Pal SK Reckamp K Yu H		0，，：	1
3	Akt inhibitors in clinical development for the treatment of cancer 显示文摘	PAL K S RECKAMP K YU H	2010	Expert Opin Investig Drugs2010，19，11：	1
4	Targeted therapies for non- small cell lung cancer: an evolving landscape 显示文摘	PAL S K FIGLIN R A RECKAMP K	2010	Mol Cancer Ther2010，9，7：	1
5	The potential and rational for COX-2 inhibitors in lung cancer显示文摘	Krysan K Reckamp K L Sharma S	2006	Anticancer Agents Med Chem2006，6，3：	1
6	Non - small cell lung cancer In the eld- erly defining treatment options 显示文摘	Vora N Reckamp K L	2008	Sere in Oncol2008，35，：	1
7	Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer显示文摘	Mao JT Cui X Reckamp K	2005	Clin Lung Cancer2005，7，：	1
8	The potential and rational for C)X-2 inhibitors in Lung cancer显示文摘	Krysan K Reckamp K L Sharma S	2006	Anticancer Agents Med Chert2006，6，3：	1
9	Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis 显示文摘	Pan J Mestas J Burdiek M D Phillips R J Thomas G V Reckamp K	2006	Mol Cancer2006，5，：	1
10	Radiofrequency ablation in lung cancer:promising results in safety and efficacy显示文摘	Suh R Reckamp K Zeidler M	2005	Oncology2005，19，10：	1
11	A phaseⅠtrial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced nonsmall cell lung cancer显示文摘	Reckamp KL Krysan K Morrow JD Milne GL Newman RA Tucker C	2006	Clin Cancer Res2006，12，111：	1
12	Stromal derived actor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metasta- sis显示文摘	Pan J Mestas J Burdick M D Phillips R J Thomas G V Reckamp K	2006	Mol Cancer2006，5，：	1
13	Stat3:A target to enhance antitu- mor immune response显示文摘	Lee H Pal SK Reckamp K	2010	Curr Top Microbiol Immunol2010，，：	1
14	CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer显示文摘	Reckamp K L Figlin R A Burdick M D	2009	BMC Cancer2009，9，：	1
15	The potential and rational for cox-2 inhibitors in lung cancer显示文摘	Krysan K Reckamp KL Sharma S		0，，3：	1
16	Radiofrequency ablation in lung cancer:promising results in safety and effficacy显示文摘	Suh R Reckamp K Zeidler M	2005	Oncology (Williston Park)2005，19，114：	1
17	The role of targeting mare-malian target of rapamycin in lung cancer显示文摘	Pal S K Figlin R A Reckamp K L	2008	Clin Lung Cancer2008，9，6：	1
18	A phase 1 trial to determine the optimal biological dose of eelecoxib when combined with erlotinib in advanced non-small cell lung cancer 显示文摘	Reckamp KL Krysan K Morrow JD	2006	Clin Cancer Res2006，12，：	1
19	STAT3: a target to enhance antitumor immune response显示文摘	Lee H Pal S K Reckamp K	2010	Curr Top Microbiol Immunol2010，344，：	1
20	Akt inhibitors in clinical development for the treatment of cancer显示文摘	Pal SK Reckamp K Yu H		0，，11：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示